NCT07005128

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 330 (estimated)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Conditions

• Small-cell Lung Cancer
• Extensive Stage Small-cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Tarlatamab	Tarlatamab will be administered as an intravenous (IV) infusion.
DRUG	Durvalumab	Durvalumab will be administered as an IV infusion.
DRUG	Carboplatin	Carboplatin will be administered as an IV infusion.
DRUG	Etoposide	Etoposide will be administered as an IV infusion.

Timeline

• Start date: 2025-08-18
• Primary completion: 2029-01-04
• Completion: 2029-07-15
• First posted: 2025-06-05
• Last updated: 2026-04-16

Locations

148 sites across 25 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, China, Denmark, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Netherlands, Poland, Portugal, Romania, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye)

Regulatory

• FDA-regulated drug study